OverviewChartNewsTraderScreen

Foghorn Therapeutics/  US3441741077  /

IEX
6/5/2024  9:59:05 PM Chg. +0.52 Volume Bid- Ask- High Low
6.19USD +9.17% 3,179
Turnover: 18,896.42		 -Bid Size: - -Ask Size: - 6.26 5.65
GlobeNewswire 5/28 Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
GlobeNewswire 5/24 Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO)...
GlobeNewswire 5/23 Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance...
GlobeNewswire 5/20 Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire 5/6 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
GlobeNewswire 4/16 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Fi...
GlobeNewswire 4/9 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibit...
GlobeNewswire 4/5 Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
GlobeNewswire 3/26 Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Con...
GlobeNewswire 3/7 Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
GlobeNewswire 3/5 Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advance...
GlobeNewswire 2/28 Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
GlobeNewswire 2/15 OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
GlobeNewswire 2/8 Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
GlobeNewswire 1/8 Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategi...
GlobeNewswire 1/5 Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
GlobeNewswire 1/3 Foghorn Therapeutics Announces CFO Departure
GlobeNewswire 12/1/2023 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibit...
GlobeNewswire 11/2/2023 Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
GlobeNewswire 10/24/2023 Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 an...
GlobeNewswire 10/13/2023 Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melan...
GlobeNewswire 10/4/2023 Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Div...
GlobeNewswire 9/5/2023 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire 8/31/2023 Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relap...
GlobeNewswire 3/11/2022 Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day